398 related articles for article (PubMed ID: 28738907)
41. Muscle Expression of Type I and Type II Interferons Is Increased in Juvenile Dermatomyositis and Related to Clinical and Histologic Features.
Moneta GM; Pires Marafon D; Marasco E; Rosina S; Verardo M; Fiorillo C; Minetti C; Bracci-Laudiero L; Ravelli A; De Benedetti F; Nicolai R
Arthritis Rheumatol; 2019 Jun; 71(6):1011-1021. PubMed ID: 30552836
[TBL] [Abstract][Full Text] [Related]
42. Complement in autoimmune inflammatory myopathies, the role of myositis-associated antibodies, COVID-19 associations, and muscle amyloid deposits.
Dalakas MC
Expert Rev Clin Immunol; 2022 Apr; 18(4):413-423. PubMed ID: 35323101
[TBL] [Abstract][Full Text] [Related]
43. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis.
Greenberg SA; Pinkus JL; Pinkus GS; Burleson T; Sanoudou D; Tawil R; Barohn RJ; Saperstein DS; Briemberg HR; Ericsson M; Park P; Amato AA
Ann Neurol; 2005 May; 57(5):664-78. PubMed ID: 15852401
[TBL] [Abstract][Full Text] [Related]
44. Idiopathic inflammatory myopathies in childhood: a brief review of 27 cases.
Lorenzoni PJ; Scola RH; Kay CS; Prevedello PG; Espíndola G; Werneck LC
Pediatr Neurol; 2011 Jul; 45(1):17-22. PubMed ID: 21723454
[TBL] [Abstract][Full Text] [Related]
45. Myopathological findings in interstitial myositis in type II polyendocrine autoimmune syndrome (Schmidt's syndrome).
Heuss D; Engelhardt A; Göbel H; Neundörfer B
Neurol Res; 1995 Jun; 17(3):233-7. PubMed ID: 7643982
[TBL] [Abstract][Full Text] [Related]
46. Polymyositis, dermatomyositis, and autoimmune necrotizing myopathy: clinical features.
Khan S; Christopher-Stine L
Rheum Dis Clin North Am; 2011 May; 37(2):143-58, v. PubMed ID: 21444016
[TBL] [Abstract][Full Text] [Related]
47. The perifascicular atrophy factor. An aid in the histological diagnosis of polymyositis.
Baumli HP; Mumenthaler M
J Neurol; 1977 Jan; 214(2):129-36. PubMed ID: 64596
[TBL] [Abstract][Full Text] [Related]
48. What more can we learn from muscle histopathology in children with dermatomyositis/polymyositis?
Wargula JC; Lovell DJ; Passo MH; Bove KE; Santangelo JD; Levinson JE
Clin Exp Rheumatol; 2006; 24(3):333-43. PubMed ID: 16870106
[TBL] [Abstract][Full Text] [Related]
49. Autoimmune muscle disease.
Mammen A
Handb Clin Neurol; 2016; 133():467-84. PubMed ID: 27112692
[TBL] [Abstract][Full Text] [Related]
50. Inclusion body myositis: clinical and pathological boundaries.
Amato AA; Gronseth GS; Jackson CE; Wolfe GI; Katz JS; Bryan WW; Barohn RJ
Ann Neurol; 1996 Oct; 40(4):581-6. PubMed ID: 8871577
[TBL] [Abstract][Full Text] [Related]
51. [Histopathologic aspects of polymyositis and dermatomyositis. Correlation with the clinical course. Study of 57 cases].
Gayraud M; Tome F; Herson S; Chevallay M; Fardeau M; Godeau P
Ann Med Interne (Paris); 1989; 140(6):445-8. PubMed ID: 2696397
[TBL] [Abstract][Full Text] [Related]
52. Prominent mitochondrial pathology in a case of refractory dermatomyositis: coincidence or concause?
Lauletta A; De Carolis L; Teresi V; Fionda L; Leonardi L; Ceccanti M; Costanzo R; Rossini E; Tufano L; Merlonghi G; Morino S; Garibaldi M
Neurol Sci; 2023 Dec; 44(12):4525-4529. PubMed ID: 37624542
[TBL] [Abstract][Full Text] [Related]
53. Dermatomyositis: Muscle Pathology According to Antibody Subtypes.
Tanboon J; Inoue M; Saito Y; Tachimori H; Hayashi S; Noguchi S; Okiyama N; Fujimoto M; Nishino I
Neurology; 2022 Feb; 98(7):e739-e749. PubMed ID: 34873015
[TBL] [Abstract][Full Text] [Related]
54. Quantitative histopathology of the inflammatory myopathies.
Ringel SP; Carry MR; Aguilera AJ; Starcevich JM
Arch Neurol; 1986 Oct; 43(10):1004-9. PubMed ID: 3753261
[TBL] [Abstract][Full Text] [Related]
55. The host defense peptide LL-37 a possible inducer of the type I interferon system in patients with polymyositis and dermatomyositis.
Lu X; Tang Q; Lindh M; Dastmalchi M; Alexanderson H; Popovic Silwerfeldt K; Agerberth B; Lundberg IE; Wick C
J Autoimmun; 2017 Mar; 78():46-56. PubMed ID: 28012697
[TBL] [Abstract][Full Text] [Related]
56. Tenascin is a useful marker in the diagnosis of inflammatory myopathies.
Müller-Felber W; Toepfer M; Müller T; Müller-Höcker J; Fischer P; Lochmüller H; Pongratz D
Eur J Med Res; 1998 Jun; 3(6):281-7. PubMed ID: 9620889
[TBL] [Abstract][Full Text] [Related]
57. Distinct interferon signatures stratify inflammatory and dysimmune myopathies.
Rigolet M; Hou C; Baba Amer Y; Aouizerate J; Periou B; Gherardi RK; Lafuste P; Authier FJ
RMD Open; 2019; 5(1):e000811. PubMed ID: 30886734
[TBL] [Abstract][Full Text] [Related]
58. Platelet-endothelial cell adhesion molecule-1 and CD146: soluble levels and in situ expression of cellular adhesion molecules implicated in the cohesion of endothelial cells in idiopathic inflammatory myopathies.
Figarella-Branger D; Schleinitz N; Boutière-Albanèse B; Camoin L; Bardin N; Guis S; Pouget J; Cognet C; Pellissier JF; Dignat-George F
J Rheumatol; 2006 Aug; 33(8):1623-30. PubMed ID: 16881117
[TBL] [Abstract][Full Text] [Related]
59. Myopathology of non-infectious inflammatory myopathies - the current status.
Hewer E; Goebel HH
Pathol Res Pract; 2008; 204(9):609-23. PubMed ID: 18514433
[TBL] [Abstract][Full Text] [Related]
60. Muscle biopsy features of idiopathic inflammatory myopathies and differential diagnosis.
Vattemi G; Mirabella M; Guglielmi V; Lucchini M; Tomelleri G; Ghirardello A; Doria A
Auto Immun Highlights; 2014 Dec; 5(3):77-85. PubMed ID: 26000159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
